<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017936</url>
  </required_header>
  <id_info>
    <org_study_id>HM20015843</org_study_id>
    <secondary_id>1R21TR003103</secondary_id>
    <nct_id>NCT04017936</nct_id>
  </id_info>
  <brief_title>Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis</brief_title>
  <acronym>MAGiC-ART</acronym>
  <official_title>Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are&#xD;
      granulomatous inflammatory infiltrates in involved tissues. Tissue commonly affected are&#xD;
      lungs, skin, eyes, lymph nodes and the heart. In this latter case, cardiac sarcoidosis (CS)&#xD;
      can lead to atrioventricular (AV) blocks, ventricular arrhythmias, heart failure (HF) and&#xD;
      sudden cardiac death. Similar to other involved organs, cardiac disease generally progresses&#xD;
      from areas of focal inflammation to scar. However, the natural history of CS is not well&#xD;
      characterized complicating an immediate and definitive diagnosis. The management of CS often&#xD;
      requires multidisciplinary care teams and is challenged by data limited to small&#xD;
      observational studies and from the high likelihood of side effects of most of the treatments&#xD;
      currently used (eg: corticosteroids, methotrexate and TNF-alfa inhibitors).&#xD;
&#xD;
      Interleukin-1 (IL-1) is the prototypical pro-inflammatory cytokine, also referred to as&#xD;
      master regulator of the inflammatory response, involved in virtually every acute process.&#xD;
      There is evidence that IL-1 plays a role in mouse model of sarcoidosis and human pulmonary&#xD;
      lesions as the presence of the inflammasome in granulomas of the heart of patients with&#xD;
      cardiac sarcoidosis, providing additional support for a role of IL-1 in the pathogenesis of&#xD;
      CS. However, IL-1 blockade has never been evaluated as a potential therapeutic agent for&#xD;
      cardiac sarcoidosis.&#xD;
&#xD;
      In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade&#xD;
      with anakinra (IL-1 receptor antagonist) in patients with cardiac sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Researchers will perform an open label randomized clinical trial of anakinra (recombinant&#xD;
      IL-1 receptor antagonist, Kineret, SOBI, Sweden) given for 4 weeks in 28 patients with&#xD;
      cardiac sarcoidosis (defined using Heart Rhythm Society diagnostic criteria).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammation marker</measure>
    <time_frame>Baseline to 28 days</time_frame>
    <description>Change in c-reactive protein in participant plasma samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac inflammation</measure>
    <time_frame>Baseline to 28</time_frame>
    <description>Change in heart function as measured by tracer activity using positron emission tomography (PET) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac fibrosis</measure>
    <time_frame>Baseline to 28</time_frame>
    <description>Change in late gadolinium enhancement evident on magnetic resonance imaging (MRI) scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious cardiac events</measure>
    <time_frame>28 days</time_frame>
    <description>Sum of hospitalizations and deaths due to cardiac causes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cardiac Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg/0.67 mL daily subcutaneous injection for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continue standard of care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Active Treatment</description>
    <arm_group_label>Anakinra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA (all 3 criteria need to be met)&#xD;
&#xD;
          -  Clinical diagnosis of cardiac sarcoidosis according to the Heart Rhythm Society or the&#xD;
             New Japanese Cardiac Sarcoidosis Guidelines (must meet one of the diagnostic pathways)&#xD;
&#xD;
          -  Heart Rhythm Society Diagnostic Criteria based on 2 diagnostic pathways:&#xD;
&#xD;
               1. Histological diagnosis from myocardial tissue - cardiac sarcoidosis is diagnosed&#xD;
                  in the presence of non-caseating granuloma on histologic examination of&#xD;
                  myocardial tissue with no alternative cause identified (including negative stain&#xD;
                  for microorganisms - as applicable);&#xD;
&#xD;
               2. Clinical diagnosis from invasive and/or non-invasive studies - it is probable&#xD;
                  that there is cardiac sarcoidosis if there is (a) histological diagnosis of&#xD;
                  extracardiac sarcoidosis and (b) one or more of the following: steroid +/-&#xD;
                  immunosuppressant responsive cardiomyopathy or heart block; unexplained reduction&#xD;
                  in LVEF (&lt;40%); unexplained sustained (spontaneous or induced) ventricular&#xD;
                  tachycardia; Mobitz type II 2nd degree or 3rd degree AV block; patchy uptake on&#xD;
                  dedicated cardiac PET (in a pattern consistent with cardiac sarcoidosis); late&#xD;
                  gadolinium enhancement on cardiac magnetic resonance (in a pattern consistent&#xD;
                  with cardiac sarcoidosis); positive gallium uptake (in a pattern consistent with&#xD;
                  cardiac sarcoidosis) and (c) other causes for the cardiac manifestation(s) have&#xD;
                  been reasonable excluded.&#xD;
&#xD;
          -  Japanese Cardiac Sarcoidosis Diagnostic Criteria:&#xD;
&#xD;
               1. Histological diagnosis group (those with positive myocardial biopsy findings)&#xD;
                  Cardiac sarcoidosis is diagnosed histologically when endomyocardial biopsy or&#xD;
                  surgical specimens demonstrate non-caseating epithelioid granulomas.&#xD;
&#xD;
               2. Clinical diagnosis group (those with negative myocardial biopsy findings or those&#xD;
                  not undergoing myocardial biopsy)&#xD;
&#xD;
        The patient is clinically diagnosed as having sarcoidosis:&#xD;
&#xD;
          1. When epithelioid granulomas are found in organs other than the heart and clinical&#xD;
             findings strongly suggestive of the above-mentioned cardiac involvement are present&#xD;
             (Table 1); or&#xD;
&#xD;
          2. When the patient shows clinical findings strongly suggestive of pulmonary or&#xD;
             ophthalmic sarcoidosis; at least 2 of the 5 characteristic laboratory findings of a&#xD;
             sarcoidosis (Table 2); and clinical findings strongly suggest the above-mentioned&#xD;
             cardiac involvement (Table 1)&#xD;
&#xD;
        TABLE 1. Clinical findings defining cardiac involvement Cardiac findings should be assess&#xD;
        based on the major criteria and the minor criteria. Clinical findings that satisfy the&#xD;
        following 1) or 2) strongly suggest the presence of cardiac involvement.&#xD;
&#xD;
          1. 2 or more of the 5 major criteria (a)-(e) are satisfied.&#xD;
&#xD;
          2. 1 of the 5 major criteria (a)-(e) and 2 or more of the 3 minor criteria (f)-(h) are&#xD;
             satisfied.&#xD;
&#xD;
        1. Major criteria&#xD;
&#xD;
          1. High-grade AV block (including complete AV block) or fatal ventricular arrhythmia&#xD;
             (e.g., sustained VT and VF)&#xD;
&#xD;
          2. Basal thinning of the ventricular septum or abnormal ventricular wall anatomy&#xD;
             (ventricular aneurysm, thinning of the middle or upper ventricular septum, regional&#xD;
             wall thickening&#xD;
&#xD;
          3. Left ventricular contractile dysfunction (LVEF &lt; 50%)&#xD;
&#xD;
          4. 67Ga citrate scintigraphy or 18F-FDG PET reveals abnormally high tracer accumulation&#xD;
             in the heart&#xD;
&#xD;
          5. Gadolinium-enhanced MRI revealed delayed contrast enhancement of the myocardium 2.&#xD;
             Minor criteria&#xD;
&#xD;
          6. Abnormal ECG findings: Ventricular arrhythmias (nonsustained VT, multifocal or&#xD;
             frequent premature ventricular contractions, bundle branch block, axis deviation, or&#xD;
             abnormal Q waves&#xD;
&#xD;
          7. Perfusion defects on myocardial perfusion scintigraphy (SPECT)&#xD;
&#xD;
          8. Endomyocardial biopsy: Monocyte infiltration and moderate or severe myocardial&#xD;
             interstitial fibrosis&#xD;
&#xD;
        Table 2. Characteristic laboratory findings of sarcoidosis 6. Bilateral hilar&#xD;
        lymphadenopathy 7. High serum angiotensin-converting (ACE) activity or elevated serum&#xD;
        lysozyme levels 8. High serum soluble interleukin-2 receptor (sIL-2R) levels 9. Significant&#xD;
        tracer accumulation in 67Ga citrate scintigraphy or 18F-FDG PET 10. A high percentage of&#xD;
        lymphocytes with a CD4CD8 ration of &gt;3.5 in BAL fluid. 11.&#xD;
&#xD;
          -  Diagnostic guidelines for isolated cardiac sarcoidosis based on New CS Guidelines in&#xD;
             Japan Prerequisite&#xD;
&#xD;
               1. No clinical findings characteristic of sarcoidosis are observed in any organs&#xD;
                  other than the heart. (The patient should be examined in detail for respiratory,&#xD;
                  ophthalmic, and skin involvement of sarcoidosis. When the patient is symptomatic,&#xD;
                  other etiologies that can affect the corresponding organs must be ruled out.)&#xD;
&#xD;
               2. 67Ga scintigraphy or 18F-FDG PET reveals no abnormal tracer accumulation in any&#xD;
                  organs other than the heart.&#xD;
&#xD;
               3. A chest CT scan reveals no shadow along the lymphatic tracts in the lungs or no&#xD;
                  hilar and mediastinal lymphadenopathy (minor axis&gt;10 mm).&#xD;
&#xD;
               1. Histological diagnosis group Isolated cardiac sarcoidosis is diagnosed&#xD;
                  histologically when endomyocardial biopsy or surgical specimens demonstrate&#xD;
                  non-caseating epithelioid granulomas.&#xD;
&#xD;
               2. Clinical diagnosis group Isolated cardiac sarcoidosis is diagnosed clinically&#xD;
                  when criterion (d) and at least 3 other major criteria (a)-(e) are satisfied.&#xD;
                  (Table 1)&#xD;
&#xD;
          -  Cardiac fluoro-deoxyglucose uptake on recent PET (performed within the prior month).&#xD;
&#xD;
          -  CRP high-sensitivty assay &gt;2 mg/l.&#xD;
&#xD;
        EXCLUSION CRITERIA (any of the following criteria would result in exclusion)&#xD;
&#xD;
          1. Age&lt;21 years;&#xD;
&#xD;
          2. Pregnancy;&#xD;
&#xD;
          3. Inability to obtain consent from patient or legally authorized representative;&#xD;
&#xD;
          4. Contraindications to treatment with Anakinra (Kineret)(i.e. prior allergic reaction to&#xD;
             the drug or to E. coli derived products or severe allergy to latex);&#xD;
&#xD;
          5. Severe anemia (Hgb&lt;8 g/dl - due to the need of more frequent blood sampling with this&#xD;
             study).&#xD;
&#xD;
          6. Acute or chronic active infections (not including treated/cured HCV with negative&#xD;
             viral load).&#xD;
&#xD;
          7. Acute or chronic inflammatory disease or immunosuppressive therapies (excluding stable&#xD;
             [&gt;1 month] oral corticosteroids at a dose of prednisone less than 0.5 mg/kg/day or&#xD;
             methotrexate).&#xD;
&#xD;
          8. Active acute or chronic psychiatric illness that in the opinion of the investigator&#xD;
             may prevent from complying with study instructions;&#xD;
&#xD;
          9. Limited English Proficiency that in the opinion of the investigator may prevent from&#xD;
             understanding the content of the informed consent form or safely completing the study&#xD;
             procedures.&#xD;
&#xD;
         10. Live vaccination within the prior month&#xD;
&#xD;
         11. Neutropenia (defined as absolute neutrophil count &lt; 1,500/ml or &lt;1,000/ml if subject&#xD;
             is African American)&#xD;
&#xD;
         12. History of malignancy within the prior 5 years (with exception of basal cell skin&#xD;
             cancer, carcinoma in-situ of the cervix or low risk prostate cancer after curative&#xD;
             therapy)&#xD;
&#xD;
         13. Participation in another concurrent intervention study within 30 day or treatment with&#xD;
             an investigational drug within 5 half-lives prior to randomization&#xD;
&#xD;
         14. Severe kidney disease (GFR &lt;30 mL/min/1.73m2)&#xD;
&#xD;
         15. Evidence of COVID-19 within the last 60 days or recent (21 days) exposure to close&#xD;
             personal contact with COVID-19.&#xD;
&#xD;
         16. [Chronic, moderate-to-severe kidney disease (GFR &lt;60 mL/min/1.73m2) or acute kidney&#xD;
             injury, or history of severe hypersensitivity reactions to gadolinium-based contrast&#xD;
             agents] - For VCU Imaging Substudy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordana Kron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordana Kron, MD</last_name>
    <phone>804-828-7565</phone>
    <email>jordana.kron@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Abbate, ME, PhD</last_name>
    <phone>804-828-0513</phone>
    <email>aabbate@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Sarcoidosis Clinic</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Crawford, MD</last_name>
      <phone>734-936-6858</phone>
      <email>thomcraw@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Mihalick, MS</last_name>
      <phone>804-628-3981</phone>
      <email>virginia.mihalick@vcuhealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

